Occupancy of the D 2 receptor has been a foundation for the mechanism of antipsychotic action for over two decades. The introduction of atypical antipsychotics and their multiple receptor profiles coupled with functional brain imaging technology has raised questions about what once was considered to be a very tight concept. We address controversial facets to the D 2 receptor's involvement in the antipsychotic mechanism and point to future clinical research directions.
How important is the D 2 receptor for the treatment of psychosis? Of all the tales of neuropharmacology, none seemed so tight nor so elegant. Antipsychotic neuroleptics, psychiatry's first wonder drugs, block the D 2 receptor, reduce the (putative) high dopamine neurotransmission of schizophrenia and diminish psychosis-nice story. I doubt that psychiatry's generation X (and Molecular Psychiatry readership) buys it the way my generation did when we were residents in the 1970s. Nevertheless, the D 2 receptor and its involvement in the antipsychotic process simply won't go away just because it has been around a long time. The two articles in this month's Molecular Psychiatry grapple with the 'D 2 question' in light of the new generation of atypical antipsychotics and the now considerable data from functional brain imaging studies. 1, 2 We see here opposing viewpoints from members of the same research team, always an interesting event! Here are some personal thoughts. I had at one time hypothesized that given its low D 2 affinity, there would/should be an 'optimal' level of D 2 occupancy needed to maximize the antipsychotic effect of clozapine-it's called betting with your clinical heart. Functional brain imaging studies, including our own, 4 confirm only clozapine's overall low levels of striatal D 2 occupancy without evidence for a crosssectional or optimal occupancy window. What strikes me most is the large individual patient differences in D 2 occupancy associated with good clinical response. Some patients respond well to clozapine with very low estimated D 2 occupancy (Ͻ25%), while others appear to 'need' near saturation levels of 80%. These findings may not sit well with Seeman and Tellerico. 1 As elegantly presented in their paper, 1 
Show me the drug!

Dirty is good
There is an old medical school joke that goes something like this: The pharmacology professor turns to the medical student and asks, 'What is the definition of a drug?' The student, without missing a beat, replies: 'A drug is a substance which when injected into an animal produces a paper.' Any good pharmacology paper writer knows that its easier to write about a compound with a clean, well defined single effect than a 'dirty' drug. Who would have developed a compound such a clozapine with its broad (dirty) admixture of effects on neurotransmitter systems? The answer is, about every major pharmaceutical company with active CNS programs, that's who. Why? Because of clinical investigation demonstrating beyond a reasonable doubt that for a substantial number of seriously mentally ill patients, interaction with serotonin, dopamine and possible noradrenergic systems provides therapeutic advantage beyond pure dopaminergic compounds. 3 Long live interactive neurotransmitter systems! Kapur's thoughtful paper 2 proposes characterization of atypical antipsychotics on the basis of the balance of receptor occupancies (and affinities) for D 2 and 5HT 2a receptors. I generally agree that the schema has validity for identifying clinical characteristics of new compounds. Does it push the envelope? I'm less sure.
Individual differences in drug response
A traditional explanation for clinical differences among schizophrenic patients, including individual variation in drug response, is to invoke different subtypes of disease. Seeman and Tellerico, 1 for example, consider subtype differences the most likely explanation for the fact that there are a substantial number of patients who do not improve clinically despite high D 2 occupancy. Is it different disease subtypes, or individual (population related) differences in the molecular (genetic) substrates of key proteins involved in the antipsychotic mechanism, which underlie drug response differences? The application of molecular biological techniques to the examination of individual differences in genes coding for the neurotransmitter receptors implicated in antipsychotic drug action, for example, may prove to be a valuable new approach for the identification of response predictors. The exponential increase in candidate genes and related polymorphisms promises greater and greater opportunity for clinical application. While the D 2 receptor shows rare structural polymorphisms, thereby limiting its value as a candidate gene for drug response association, the search for polymorphisms in regulatory regions is underway and, if successful, could bring new 'opportunity' for the D 2 receptor gene's clinical application.
So where does this leave us with regard to the D 2 receptor? Certainly, it can't be abandoned as at least the starting point for understanding how antipsychotics work. Individual differences in drug response, including association with candidate gene polymorphisms, hold the promise of moving the field, whether its focus is on second and third messenger systems, or other neurotransmitter systems with dopaminergic interaction. I look forward to the next decade as being the golden age of the treatment of schizophrenia; not because of the current new generation of compounds but what they will teach us and how we will use that information to advance the pharmacotherapy of schizophrenia.
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